Literature DB >> 1810455

Tumour regression by IL-2 mediated stagnation of blood flow.

H J De Mik1, J W Koten, R A Maas, H F Dullens, W Den Otter.   

Abstract

The histology of Interleukin-2 induced tumour regression is presented. DBA/2 mice were injected simultaneously ip (intraperitoneally) and sc (subcutaneously) with 2 x 10(4) and 2 x 10(5) syngeneic SL2 lymphosarcoma cells, respectively. After treatment with 20,000 U IL-2 given ip at days 10-14, 50% of these mice survive. Histological analysis of the sc tumours showed that stagnation of blood flow and an occurrence of sudden massive necrosis were indicative of tumour regression. We hypothesize that peritoneal lymphocytes, activated by the ip tumour cells and IL-2, home in the sc tumour. There these activated lymphocytes produce lymphokines and trigger off other infiltrate cells to do similarly. This causes vascular leakage which leads to an increased intratumoural interstitial hydrostatic pressure. Subsequently circulatory obstruction and tumour necrosis occurs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810455

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  4 in total

1.  Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up.

Authors:  W Den Otter; F W Hill; W R Klein; J W Koten; P A Steerenberg; P H De Mulder; C Rhode; R Stewart; J A Faber; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

2.  Specific tumor memory induced by polyethylene-glycol-modified interleukin-2 requires both helper and cytotoxic T cells.

Authors:  L T Balemans; P A Steerenberg; B H Kremer; F J Koppenhagen; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

3.  Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

Authors:  L T Balemans; V Mattijssen; P A Steerenberg; B E Van Driel; P H De Mulder; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

4.  Local therapy of cancer with free IL-2.

Authors:  Willem Den Otter; John J L Jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan Willem Koten
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.